Preparing for COMPASS Pathways’ Phase Data Readout: 2b, or not to be? Post published:November 5, 2021 Post category:Analysis/News
Psychedelic Bulletin: COMPASS Targets PTSD; Detroit Decriminalizes Psychedelics; We Speak to Rick Doblin Post published:November 5, 2021 Post category:Psychedelic Bulletin
PharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye Diseases Post published:November 5, 2021 Post category:Press Release
MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board Post published:November 5, 2021 Post category:Press Release
Cybin Granted DEA Schedule I Manufacturing License Post published:November 4, 2021 Post category:Press Release
MINDCURE Provides Update on Studies and Clinical Trials Post published:November 4, 2021 Post category:Press Release
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for PTSD Post published:November 3, 2021 Post category:Press Release
Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients Post published:November 3, 2021 Post category:Press Release
PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch Post published:November 3, 2021 Post category:Press Release
Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully Added to the Natural Health Products Ingredients Database (NHPID) of Canada Post published:November 3, 2021 Post category:Press Release